25mg - White round tablets with a breakline on one side. Each tablet contains 25 mg clindamycin (as hydrochloride).

300mg - A plain white to off white tablet with a cross breakline on one side. The tablets can be divided into halves or quarters. Each tablets contains 300 mg clindamycin (as hydrochloride)

For use in dogs.

Clinacin tablets are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, Fusobacterium necrophorum, Clostridium perfringens and osteomyelitis caused by Staphylococcus aureus. Clinacin tablets can also be used to help provide antimicrobial cover during dental procedures.

For oral administration.

1. For treatment of infected wounds, abscesses, oral cavity/dental infections, administer 5.5mg clindamycin per kg bodyweight twice daily for 7 - 10 days. Treatment may be extended to a maximum of 28 days based on clinical judgement. If no improvement is seen within 4 days, the sensitivity of the pathogens involved should be redetermined.

2. For the treatment of superficial pyoderma administer 11mg clindamycin per kg bodyweight once daily. Continue treatment for at least 21 days.

3. For the treatment of osteomyelitis administer 11 mg clindamycin per kg bodyweight twice daily for at least 28 days. If no improvement is seen within 14 days, the sensitivity of the pathogens involved should be redetermined.

4. To help provide antimicrobial cover during dental procedures, a 10 day course of 5.5 mg/kg every 12 hours is recommended (i.e. beginning 5 days before the intended procedure and continuing for 5 days thereafter).

Return any divided tablets to the blister pack or container and use within 72 hours. Divided tablets should be used at the next administration. Any divided tablets remaining after the last administration of the product should be discarded.

Tablets can be divided into halves or quarters to ensure accurate dosing.

To break a cross scored tablet into quarters, place the tablet on an even surface with the scored side up and apply pressure on the middle with your thumb.

To break a tablet into two halves, place the tablet on an even surface with the scored side up, hold one half of the tablet and press down on the other half.

Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations. Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants.

Before use of Clinacin tablets, the identification of causative pathogenic micro-organisms should be carried out and their susceptibility to clindamycin should be established.

Clindamycin and lincomycin show parallel-resistance. There is a partial cross-resistance to erythromycin and other macrolide-antibiotics.

Symptoms of overdose include vomiting, inappetency and diarrhoea. In such cases, treatment should be stopped immediately and the dogs treated symptomatically.

Clindamycin sometimes causes the overgrowth of non sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures should be taken according to the clinical situation.

Vomiting and diarrhoea are observed occasionally.

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy.

While high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established.

Neuromuscular blocking effects have been observed with clindamycin possibly leading to an increase of efficacy of other neuromuscular blocking agents. The concomitant use of such drugs must be handled with care.

ClinacinTablets are contra-indicated in animals hypersensitive to clindamycin or lincomycin preparations.

Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants.

Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they may antagonise each other at their site of action.

Clindamycin sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation. Vomiting and diarrhoea have occasionally been observed.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

Clindamycin and lincomycin show parallel resistance.

Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolide antibiotics.

Before use of Clinacin tablets, the identification of causative pathogenic micro-organisms should be carried out and their susceptibility to clindamycin should be established.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. CLINACIN TABLETS should be used with caution in animals receiving such agents.

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy.

While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established. Therefore, the administration of the veterinary medicinal product during pregnancy and lactation should be the subject of a benefit/risk assessment by the veterinarian.

The bioavailability of the product is higher in fasting dogs compared to non-fasting dogs. Symptoms of overdose include vomiting, inappetance and diarrhoea. In such cases, treatment should be stopped immediately and the dogs treated symptomatically.

For animal treatment only.

Keep out of the reach of children.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

This veterinary medicinal product does not require any special storage conditions.

25mg - Polyethylene bottles containing 100 tablets.

300mg - white HDPE bottle containing 80 tablets.

Clindamycin is an antibiotic with bacteriostatic action. Bactericidal actions have also been reported. Clindamycin is rapidly absorbed from the gastro-intestinal tract.